Watch video: HIV #vaccine scientific progress and challenges by IAVI
Hansi Dean, Director New Alliances at International AIDS Vaccine Initiative (IAVI) delivered a presentation on HIV vaccine scientific progress..
Posts in the HIV category
#wvcusa – Margaret McGlynn, President & CEO, IAVI LIVE: Exciting new advances in HIV
What are the prospects for finally developing a safe, effective and accessible vaccine to prevent AIDS? Dr Margaret McGlynn answered..
Could #HIV one day be treated as nothing more than a minor infection?
That's what researchers at the National Biotech Center in Madrid are hoping to eventually achieve with MVA-B, their early-stage HIV vaccine...
Your 2012 funding prayers answered
Seeking a way to fast track your Seed, Start-Up, Series A, B, Mezzanine or Bridge financing? Speed Venture at World Vaccine Congress Washington..
Two steps forward one step back in AIDS #vaccine progress
Indian scientists working on AIDS vaccine in clinical trials since 2006 are unable to make further progress Read the original..
HIV #vaccines: Researchers present much-anticipated correlates data from RV144
This guest blog post was provided by IAVI Report, and is written by Managing Editor Kristen Jill Kresge. At the first plenary session of AIDS..
#Vaccine market forecasted to double within the next five years
The rapidly growing vaccine market is said to double its 2007 value in the next five years due to fear of breakouts, lack of competitive..
Novel antibodies could lead to AIDS #vaccine
Researchers sponsored by the International AIDS Vaccine Initiative (IAVI) have isolated 17 novel antibodies against HIV, an achievement that..
GeoVax awarded $3.6m for HIV/AIDS #vaccine program
GeoVax, an Atlanta-based, biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today..
Inovio posts positive preclinical #HIV #vaccine results
Blue Bell, PA-based Inovio Pharmaceuticals has recently published data from two preclinical HIV trials. The results demonstrate the vaccines'..
